HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
- DOI
- 10.1200/jco.23.01476
- Published
- 2023-12-10
- Container
- Journal of Clinical Oncology
- Publisher
- American Society of Clinical Oncology (ASCO)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1200/jco.23.01476,
title = {HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy},
author = {Helena A. Yu and Yasushi Goto and Hidetoshi Hayashi and Enriqueta Felip and James Chih-Hsin Yang and Martin Reck and Kiyotaka Yoh and Se-Hoon Lee and Luis Paz-Ares and Benjamin Besse and Paolo Bironzo and Dong-Wan Kim and Melissa L. Johnson and Yi-Long Wu and Thomas John and Steven Kao and Toshiyuki Kozuki and Erminia Massarelli and Jyoti Patel and Egbert Smit and Karen L. Reckamp and Qian Dong and Pomy Shrestha and Pang-Dian Fan and Parul Patel and Andrea Sporchia and David W. Sternberg and Dalila Sellami and Pasi A. Jänne},
year = {2023},
journal = {Journal of Clinical Oncology},
doi = {10.1200/jco.23.01476},
url = {https://doi.org/10.1200/jco.23.01476}
}RIS
TY - JOUR TI - HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy AU - Helena A. Yu AU - Yasushi Goto AU - Hidetoshi Hayashi AU - Enriqueta Felip AU - James Chih-Hsin Yang AU - Martin Reck AU - Kiyotaka Yoh AU - Se-Hoon Lee AU - Luis Paz-Ares AU - Benjamin Besse AU - Paolo Bironzo AU - Dong-Wan Kim AU - Melissa L. Johnson AU - Yi-Long Wu AU - Thomas John AU - Steven Kao AU - Toshiyuki Kozuki AU - Erminia Massarelli AU - Jyoti Patel AU - Egbert Smit AU - Karen L. Reckamp AU - Qian Dong AU - Pomy Shrestha AU - Pang-Dian Fan AU - Parul Patel AU - Andrea Sporchia AU - David W. Sternberg AU - Dalila Sellami AU - Pasi A. Jänne PY - 2023 JO - Journal of Clinical Oncology DO - 10.1200/jco.23.01476 UR - https://doi.org/10.1200/jco.23.01476 ER -
APA
Yu, H. A., Goto, Y., Hayashi, H., Felip, E., Yang, J. C., Reck, M., Yoh, K., Lee, S., Paz-Ares, L., Besse, B., Bironzo, P., Kim, D., Johnson, M. L., Wu, Y., John, T., Kao, S., Kozuki, T., Massarelli, E., Patel, J., Smit, E., Reckamp, K. L., Dong, Q., Shrestha, P., Fan, P., Patel, P., Sporchia, A., Sternberg, D. W., Sellami, D., & Jänne, P. A. (2023). HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01476
Source records
- crossref · retrieved 2026-09-26T07:17:52.694Z